Short Interest in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Increases By 1,465.0%

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) was the recipient of a significant growth in short interest in the month of June. As of June 15th, there was short interest totalling 62,600 shares, a growth of 1,465.0% from the May 31st total of 4,000 shares. Approximately 27.3% of the company’s shares are sold short. Based on an average daily trading volume, of 363,500 shares, the short-interest ratio is presently 0.2 days.

CNS Pharmaceuticals Stock Down 4.8 %

Shares of CNSP stock opened at $1.58 on Friday. The business’s fifty day moving average is $7.87 and its 200 day moving average is $22.58. CNS Pharmaceuticals has a twelve month low of $1.55 and a twelve month high of $137.50.

CNS Pharmaceuticals (NASDAQ:CNSP) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($20.50) earnings per share for the quarter.

Institutional Investors Weigh In On CNS Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Armistice Capital LLC purchased a new stake in CNS Pharmaceuticals in the fourth quarter worth $155,000. Virtu Financial LLC boosted its holdings in CNS Pharmaceuticals by 616.6% in the first quarter. Virtu Financial LLC now owns 94,246 shares of the company’s stock worth $34,000 after acquiring an additional 81,094 shares in the last quarter. Finally, Smith Anglin Financial LLC bought a new stake in CNS Pharmaceuticals in the fourth quarter worth $64,000. 14.02% of the stock is owned by hedge funds and other institutional investors.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.